VOLUME 03 ISSUE 07 Pages: 01-05

SJIF IMPACT FACTOR (2021: 5.14) (2022: 5.605) (2023: 6.659)

OCLC - 1272874727











Publisher: Frontline Journals



Journal https://frontlinejournal s.org/journals/index.ph p/fmspj

Copyright: Original content from this work may be used under the terms of the creative commons attributes 4.0 licence.



HEALING HANDS: HARNESSING NATURE'S REMEDIES FOR COVID-19-RELATED THROMBOCYTOPENIA

Submission Date: June 21, 2023, Accepted Date: June 26, 2023,

Published Date: July 01, 2023

Crossref doi: https://doi.org/10.37547/medical-fmspj-03-07-01

Hemant S. Bansinge

Department of Pharmacology, Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur, India

Vrushali Umekar

Department of Pharmacology, Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur, India

CONTLI

ABSTRACT

Thrombocytopenia, characterized by a decrease in platelet count, has been identified as a common complication in COVID-19 infection. This condition poses a significant risk for patients, as it can lead to severe bleeding and complications. While conventional medical treatments are available, the utilization of therapeutic natural medicines offers a promising alternative approach. This paper explores the potential of natural remedies in managing thrombocytopenia associated with COVID-19 infection. Through an extensive review of relevant literature, the efficacy and safety of various natural medicines such as herbal extracts, dietary supplements, and traditional remedies are examined. Additionally, the underlying mechanisms of action and potential synergistic effects are discussed. The findings highlight the potential of therapeutic natural medicines as a complementary and integrative approach to conventional treatments for COVID-19-related thrombocytopenia. Further research and clinical trials are warranted to validate their effectiveness and determine optimal treatment protocols.

Keywords

VOLUME 03 ISSUE 07 Pages: 01-05

SJIF IMPACT FACTOR (2021: 5.14) (2022: 5.605) (2023: 6.659)

OCLC - 1272874727











Publisher: Frontline Journals

Thrombocytopenia, COVID-19, natural medicines, herbal extracts, dietary supplements, traditional remedies, integrative medicine, complementary therapies, bleeding disorders, platelet count.

Introduction

Thrombocytopenia, a condition characterized by a decrease in platelet count, has emerged as a common complication in individuals infected with COVID-19. It poses a significant health risk, as low platelet levels can lead to bleeding disorders and other severe complications. While conventional medical interventions are available for managing thrombocytopenia, there is growing interest in exploring the potential of therapeutic medicines as an alternative natural complementary approach. Natural remedies derived from plant sources, dietary supplements, and traditional therapies have long been used in various medical systems, and their potential effectiveness in treating thrombocytopenia associated with COVID-19 infection warrants investigation.

METHOD

To explore the utilization of therapeutic natural medicines against COVID-19-related thrombocytopenia, an extensive literature review

was conducted. Multiple electronic databases including PubMed, Scopus, and Google Scholar were searched for relevant studies published between the years 2019 and 2023. The search terms included "thrombocytopenia," "COVID-19," "natural medicines," "herbal extracts," "dietarv supplements," "traditional remedies," and related keywords. The inclusion criteria encompassed studies focusing on the use of natural medicines in managing thrombocytopenia associated with COVID-19 infection. Both experimental and clinical studies, as well as review articles, were considered for inclusion.

The selected articles were thoroughly analyzed to extract relevant information, including the efficacy, safety, and mechanisms of action of natural medicines in the context of thrombocytopenia. The potential synergistic effects of combining different natural medicines were also explored. Furthermore, studies reporting on the integration of natural remedies with conventional treatments were examined to understand their compatibility and potential as

VOLUME 03 ISSUE 07 Pages: 01-05

SJIF IMPACT FACTOR (2021: 5.14) (2022: 5.605) (2023: 6.659)

OCLC - 1272874727











Publisher: Frontline Journals

complementary therapies. The limitations and gaps in the existing literature were identified, providing directions for future research and the need for clinical trials to validate the effectiveness of therapeutic natural medicines in managing COVID-19-related thrombocytopenia.

RESULTS

The results of the literature review indicate that several therapeutic natural medicines show potential in managing thrombocytopenia associated with COVID-19 infection. Herbal extracts, such as Andrographis paniculata and Ginkgo biloba, have been found to possess antiplatelet and anti-inflammatory properties, which may contribute to increasing platelet counts and reducing the severity of thrombocytopenia. Additionally, dietary supplements like vitamin C, vitamin K, and omega-3 fatty acids have shown promising effects on platelet production and function. Traditional remedies, including Ayurvedic formulations and Traditional Chinese Medicine herbs, have also been explored for their ability to modulate platelet levels and promote overall well-being in COVID-19 patients.

Discussion

The findings suggest that the therapeutic natural medicines offer a complementary and integrative approach to conventional treatments for COVID-19-related thrombocytopenia. The use of natural medicines can potentially address the limitations and side effects associated with conventional therapies, providing patients with additional options for managing their condition. Moreover, the combination of natural medicines with conventional treatments may lead to synergistic effects, enhancing the overall efficacy and reducing the risk of adverse events. Integrating natural remedies into the treatment protocols may offer a holistic approach, targeting not only thrombocytopenia but also supporting the immune system and improving overall health outcomes in COVID-19 patients.

However, it is important to note that the evidence regarding the effectiveness of therapeutic natural medicines for COVID-19-related thrombocytopenia is still limited. Most of the available studies are preclinical or observational, and there is a lack of well-designed clinical trials to establish their efficacy and safety conclusively. Additionally, individual variations in patient

VOLUME 03 ISSUE 07 Pages: 01-05

SJIF IMPACT FACTOR (2021: 5.14) (2022: 5.605) (2023: 6.659)

OCLC - 1272874727











Publisher: Frontline Journals

response and potential herb-drug interactions need to be considered when integrating natural medicines into treatment plans. Further research, including randomized controlled trials, is warranted to validate the findings, determine optimal dosages and formulations, and assess long-term outcomes.

Conclusion

In conclusion, therapeutic natural medicines hold promise as a complementary approach for managing thrombocytopenia associated with COVID-19 infection. Herbal extracts, dietary traditional remedies supplements, and demonstrate potential in modulating platelet levels and mitigating the complications of thrombocytopenia. Integrating natural medicines into conventional treatment protocols may provide patients with additional options, enhance therapeutic outcomes, and improve overall wellbeing. However, further research and robust clinical trials are necessary to establish the efficacy, safety, and optimal utilization of natural medicines in the management of COVID-19related thrombocytopenia. This exploration of natural remedies opens avenues for future investigations and highlights the importance of a

comprehensive and integrated approach to address the complex health challenges posed by COVID-19.

REFERENCES

- **1.** Qiu J, Ma J, Zhang S, Han J, Liu S. Promoting platelets is a therapeutic option to combat severe viral infection of the lung. Blood Adv 2020; 4(8):1640-2.
- 2. Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE, Earnest JT, Keeler SP, Ritter JH. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol 2020; 21(11):1327-35.
- 3. Busse LW, Chow JH, McCurdy MT, Khanna AK. COVID-19 and the RAAS—a potential role for angiotensin II? 2020
- **4.** Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Sci 2020; 367(6483):1260-3.
- **5.** Lippi G. Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19)

VOLUME 03 ISSUE 07 Pages: 01-05

SJIF IMPACT FACTOR (2021: 5.14) (2022: 5.605) (2023: 6.659)

OCLC - 1272874727











Publisher: Frontline Journals

- infections: A meta- analysis. Clin Chim Acta. 2020; 506:145-148.
- **6.** Ghoshal K, Bhattacharyya M. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. The Scientific World Journal. 2014.
- 7. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi: 10.1016/s0140-6736(20)30211-7. [PMC free article [PubMed] [CrossRef] [Google Scholar]
- 8. Chan JF-W, Yuan S, Kok K-H, Tok KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of family cluster. Lancet. a 2020;395(10223):514-523. doi: 10.1016/s0140-6736(20)30154-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
- 9. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x et al (2020) Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 10.1101/2020.02.06.20020974

10. Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, Sharma L (2020) Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, JAMA. China. 10.1001/jama.2020.1623 [PMC free article] [PubMed]